GNANAKUMARAN GNANASEGARAM ET AL: "Technology evaluation: mepolizumab, GlaxoSmithKline" CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, vol. 5, no. 3, 1 June 2003 (2003-06-01), pages 321-325, XP009132121 ISSN: 1464-8431 (B1)

HART TIMOTHY K ET AL: "Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys" August 2001 (2001-08), JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, VOL. 108, NR. 2, PAGE(S) 250-257 , XP002577858 ISSN: 0091-6749 * abstract; figure 3 * (B1)

LECKIE ET AL: "Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response" LANCET THE, LANCET LIMITED. LONDON, GB LNKD- DOI:10.1016/S0140-6736(00)03496-6, vol. 356, no. 9248, 23 December 2000 (2000-12-23), pages 2144-2148, XP005071953 ISSN: 0140-6736 (B1)

ZIA-AMIRHOSSEINI P ET AL: "Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 291, no. 3, December 1999 (1999-12), pages 1060-1067, XP002577859 ISSN: 0022-3565 (B1)

US-A1- 2003 059 429 (B1)

US-A1- 2003 194 404 (B1)

ZIA-AMIRHOSSEINI ET AL: "Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in mild asthmatics" CLINICAL PHARMACOLOGY AND THERAPEUTICS, NATURE PUBLISHING GROUP, US LNKD- DOI:10.1016/S0009-9236(99)80120-9, vol. 65, no. 2, 1 February 1999 (1999-02-01), page 147, XP005467519 ISSN: 0009-9236 (B1)

REVILL P ET AL: "Mepolizumab. Humanized anti-IL-5 monoclonal antibody, Treatment of hypereosinophilic syndromes" DRUGS OF THE FUTURE, vol. 32, no. 10, October 2007 (2007-10), pages 868-873, XP002577860 ISSN: 0377-8282 (B1)